Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein Sells 3,470 Shares

Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein sold 3,470 shares of Insmed stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $65.70, for a total value of $227,979.00. Following the sale, the chief financial officer now directly owns 114,736 shares of the company’s stock, valued at approximately $7,538,155.20. This trade represents a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Sara Bonstein also recently made the following trade(s):

• On Friday, January 10th, Sara Bonstein sold 1,066 shares of Insmed stock. The shares were sold at an average price of $63.72, for a total value of $67,925.52.

Insmed Stock Down 0.7 %

NASDAQ:INSM opened at $65.25 on Friday. The company has a market cap of $11.67 billion, a PE ratio of -11.76 and a beta of 1.12. The stock has a 50-day simple moving average of $71.23 and a 200 day simple moving average of $72.42. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $80.53.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The firm had revenue of $93.40 million for the quarter, compared to the consensus estimate of $93.36 million. The firm’s quarterly revenue was up 18.1% on a year-over-year basis. During the same period in the prior year, the company earned ($1.10) earnings per share. On average, sell-side analysts expect that Insmed Incorporated will post -5.44 EPS for the current fiscal year.

Institutional Investors Weigh In On Insmed

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. CIBC Asset Management Inc grew its holdings in shares of Insmed by 3.5% in the 3rd quarter. CIBC Asset Management Inc now owns 4,438 shares of the biopharmaceutical company’s stock valued at $324,000 after acquiring an additional 149 shares in the last quarter. Commerce Bank boosted its position in Insmed by 2.4% during the third quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company’s stock valued at $499,000 after purchasing an additional 163 shares during the last quarter. GAMMA Investing LLC boosted its position in Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 224 shares during the last quarter. Atomi Financial Group Inc. grew its stake in Insmed by 1.4% in the third quarter. Atomi Financial Group Inc. now owns 23,248 shares of the biopharmaceutical company’s stock valued at $1,697,000 after purchasing an additional 314 shares in the last quarter. Finally, V Square Quantitative Management LLC acquired a new position in shares of Insmed during the 3rd quarter worth approximately $30,000.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Truist Financial reaffirmed a “buy” rating and issued a $105.00 price target (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 target price on shares of Insmed in a research note on Friday, November 1st. Bank of America lifted their price target on shares of Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a report on Friday, November 22nd. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, Insmed has an average rating of “Moderate Buy” and an average price target of $83.67.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.